Inflammatory and immune responses induced by nanomaterials: Challenges and opportunities for future nanotherapies

Nanotechnology Perceptions

Volumn 5, Issue 3, 2009, Pages 195-203

  Cubillos Ruiz, Juan R ^a   Hoopes, Jack ^a   Fiering, Steven ^a   Conejo Garcia, Jose R ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952357270     PISSN: 16606795     EISSN: None     Source Type: Journal    
DOI: 10.4024/N13CU09A.ntp.05.03     Document Type: Article

References (30)

1. Xia, T., Li, N. & Nel, A.E. Potential health impact of nanoparticles. A. Rev. Public Health (2009).
2. Dobrovolskaia, M.A. & McNeil, S.E. Immunological properties of engineered nanomaterials. Nature Nanotechnol. 2 (2007) 469-478.
3. Nel, A.E. et al. Understanding biophysicochemical interactions at the nano-bio interface. Nature Materials 8 (2009) 543-557.
4. Conner, S.D. & Schmid, S.L. Regulated portals of entry into the cell. Nature 411 (2003) 37-44.
5. Manolova, V. et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38 (2008) 1404-1413.
6. Raynal, I. et al. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Investigations Radiol. 39 (2004) 56-63. (Pubitemid 38030177)
7. Goya, G.F. et al. Dendritic cell uptake of iron-based magnetic nanoparticles. Cell Biol. Int. 32 (2008) 1001-1005.
8. Berwin, B. et al. Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells. EMBO J. 11 (2003) 6127-6136. (Pubitemid 37463255)
9. Hillaireau, H. & Couvreur, P. Nanocarriers' entry into the cell: relevance to drug delivery. Cellular Mol. Life Sci. 66 (2009) 2873-2896.
10. Cubillos-Ruiz, J. et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumourassociated dendritic cells via TLR5 to elicit therapeutic antitumour immunity. J. Clin. Invest. 119 (2009)2231-2244.
11. Poeck, H. et al. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nature Med. 14(2008) 1256-1263.
12. Sadauskas, E. et al. Protracted elimination of gold nanoparticles from mouse liver. Nanomedicine 5 (2009) 162-169.
13. Dong, L., Gao, S., Diao, H., Chen, J. & Zhang, J. Galactosylated low molecular weight chitosan as a carrier delivering oligonucleotides to Kupffer cells instead of hepatocytes in vivo. J. Biomed. Mater. Res. A 84 (2008) 777-784. (Pubitemid 351237795)
14. Hu, Y. et al. Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pHresponsive core-shell nanoparticles. Nano Lett. 7 (2007) 3056-3064.
15. Nayak, J.V. et al. Phagocytosis induces lysosome remodeling and regulated presentation of particulate antigens by activated dendritic cells. J. Immunol. 177 (2006) 8493-8503.
16. Fischer, D., Li, Y., Ahlemeyer, B., Krieglstein, J. & Kissel, T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 24 (2003) 1121-1131. (Pubitemid 36069121)
17. Russell, D.G, Vanderven, B.C., Glennie, S., Mwandumba, H. & Heyderman, R.S. The macrophage marches on its phagosome: dynamic assays of phagosome function. Nature Rev. Immunol. 9 (2009) 594-600.
18. Hise, A. G. et al. An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans. Cell Host Microbe 5 (2009) 487-497.
19. Martinon, R, Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 (2006) 237-241. (Pubitemid 43372104)
20. Hornung, V. et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nature Immunol. 9 (2008) 847-856.
21. Hayashi, M.A. et al. Cytotoxic effects of crotamine are mediated through lysosomal membrane permeabilization. Toxicon 52 (2008) 508-517.
22. Demento, S. L. et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 27 (2009) 3013-3021.
23. Huarte, E. et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumour immunity. Cancer Res. 68 (2008) 7684-7691.
24. Burd, R. et al. Tumour cell apoptosis, lymphocyte recruitment and tumour vascular changes are induced by low temperature, long duration (fever-like) whole body hyperthermia. J. Cell Physiol. 177(1998)137-147. (Pubitemid 28421530)
25. Ostberg, J.R. & Repasky, E.A. Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function. Cancer Immunol. Immunother. 55 (2006) 292-298.
26. van Bruggen, I., Robertson, T.A. & Papadimitriou, J.M. The effect of mild hyperthermia on the morphology and function of murine resident peritoneal macrophages. Exp. Mol. Pathol. 55 (1991) 119-134.
27. Srivastava, P. Roles of heat-shock proteins in innate and adaptive immunity. Nature Rev. Immunol. 2 (2002) 185-194. (Pubitemid 37328765)
28. Ito, A., Honda, H. & Kobayashi, T. Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of "heat-controlled necrosis" with heat shock protein expression. Cancer Immunol. Immunother. 55 (2006) 320-328.
29. Ranney, D. et al. Dermatan carriers for neovascular transport targeting, deep tumour penetration and improved therapy. J. Control Release 109 (2005) 222-235. (Pubitemid 41737266)
30. Gabrilovich, D.I. et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67 (2007) 425; author reply p. 426.